Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,028.00
Bid: 11,850.00
Ask: 12,300.00
Change: 0.00 (0.00%)
Spread: 450.00 (3.797%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 6-Oil slips further on Europe demand concerns

Wed, 17th Mar 2021 05:25

* API report shows surprise drop in U.S. crude inventories

* No policy shift expected by U.S. Federal Reserve

* IEA says demand won't reach pre-pandemic level until 2023

* Coming up: EIA report, 1430 GMT
(Updates prices, adds French COVID-19 measures, WHO on vaccine)

By Alex Lawler

LONDON, March 17 (Reuters) - Oil slipped for a fourth day on
Wednesday as concerns about weaker demand in Europe outweighed
an industry report that showed U.S. crude inventories fell
unexpectedly last week.

Several European countries have paused the use of
AstraZeneca's COVID-19 vaccine on worries over possible side
effects. Germany is seeing rising coronavirus cases, Italy is
imposing a nationwide Easter lockdown and France plans to impose
tougher curbs.

Brent crude was down 38 cents, or 0.6%, at $68.01 a
barrel by 1410 GMT, having pared earlier losses. U.S. West Texas
Intermediate (WTI) crude dropped 35 cents, or 0.5%, to
$64.45.

"The suspension will not do the bloc's economic and fuel
recovery any favours," said Stephen Brennock of oil broker PVM.
"The hope now is that Europe can get its sluggish vaccine
rollout back on track."

A World Health Organization (WHO) vaccine safety panel on
Wednesday said the benefits of the AstraZeneca vaccine
outweigh its risks and recommends that vaccinations continue.

Oil prices were also pressured by the latest reports from
the International Energy Agency, which said a supercycle is
unlikely and demand is not expected to return to pre-pandemic
levels until 2023.

"IEA's report has triggered action among oil traders," said
Naeem Aslam of Avatrade. "We have seen some selling."

Still, oil has recovered from historic lows reached last
year as demand collapsed, buoyed by record oil output cuts by
the Organization of the Petroleum Exporting Countries (OPEC) and
its allies. Brent reached $71.38 on March 8, its highest since
Jan. 8, 2020.

The market gained support, however, from American Petroleum
Institute data, which trading sources said Ushowed U.S. crude
inventories fell by 1 million barrels last week. Analysts had
expected a rise.

Traders will be looking to the official U.S. Energy
Information Administration report at 1430 GMT for confirmation
of the API figures.

Investors are also looking to the results of the U.S.
central bank's Federal Open Market Committee meeting. No policy
shift is expected.

A rising dollar ahead of the Fed's announcement was also a
headwind for oil because a stronger dollar makes crude more
expensive for holders of other currencies.
(Additional reporting by Roslan Khasawneh in Singapore and
Sonali Paul in Melbourne; Editing by Jacqueline Wong and David
Goodman)

More News
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.